In short
Paxalisib is an investigational drug being studied in clinical trials for the treatment of various types of brain cancer, including glioblastoma and brain metastases. This article summarizes key information about ongoing clinical trials evaluating paxalisib's safety and efficacy in patients with brain tumors.
What is Paxalisib?
Paxalisib is a new drug being studied for the treatment of various brain cancers. It's also known by several other names, including GDC-0084, GDC0084, and PI3K Inhibitor GDC-0084. This medication is part of a class of drugs called PI3K/mTOR inhibitors, which means it works by blocking certain proteins that cancer cells need to grow.
How Paxalisib Works
Paxalisib is designed to target a specific pathway in cancer cells called the PI3K/AKT/mTOR pathway. This pathway is like a communication system that tells cancer cells to grow and divide. By blocking this pathway, Paxalisib aims to slow down or stop the growth of cancer cells. What makes Paxalisib special is its ability to cross the blood-brain barrier, which is a protective layer that prevents many drugs from reaching the brain. This means Paxalisib can potentially treat brain cancers more effectively than some other medications.
Conditions Treated with Paxalisib
Paxalisib is being studied for several types of brain cancers, including:
- Glioblastoma (GBM): This is an aggressive type of brain cancer that Paxalisib is being tested on in both newly diagnosed and recurrent cases.
- Diffuse Intrinsic Pontine Glioma (DIPG): A rare and aggressive brain tumor that typically affects children.
- Diffuse Midline Glioma (DMG): Another type of brain tumor that is often difficult to treat.
- Brain Metastases: These are cancer cells that have spread to the brain from other parts of the body.
Current Clinical Trials
Paxalisib is currently being studied in several clinical trials to determine its effectiveness and safety. Some of these trials include:
- A study for newly diagnosed glioblastoma patients, testing Paxalisib in combination with radiation therapy and chemotherapy.
- A trial for patients with brain metastases from various types of cancer.
- A study combining Paxalisib with other treatments for diffuse midline gliomas in children and young adults.
- A trial testing Paxalisib along with a special diet (ketogenic diet) and another medication called metformin for glioblastoma patients.
Dosage and Administration
Paxalisib is taken orally, usually in the form of tablets. The dosage can vary depending on the specific trial and condition being treated. Some common dosing regimens include:
- 45 mg taken orally once daily for 28 days, potentially increasing to 60 mg if well-tolerated.
- 21 mg/m² taken orally daily for 28-day cycles.
It's important to note that these dosages are still being studied, and the optimal dose may change as more research is conducted.
Potential Side Effects
As with any medication, Paxalisib may cause side effects. While the full range of side effects is still being studied, some potential effects that researchers are monitoring include:
- Changes in blood cell counts
- Alterations in liver function
- Effects on heart function
- Changes in blood sugar levels
These potential side effects are being closely monitored in clinical trials to ensure patient safety.
Future Research and Combinations
Researchers are exploring various ways to use Paxalisib most effectively. This includes:
- Combining Paxalisib with other cancer treatments like radiation therapy and chemotherapy.
- Testing Paxalisib alongside dietary changes, such as a ketogenic diet (high-fat, low-carbohydrate diet).
- Using Paxalisib in combination with other targeted therapies based on a patient's specific tumor characteristics.
These ongoing studies aim to find the most effective ways to use Paxalisib to help patients with various types of brain cancers.